Asset Details
Do you wish to reserve the book?
Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial
Do you wish to request the book?
Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial
2016
Overview
Purpose
Paclitaxel can cause an acute pain syndrome (P-APS), considered to be an acute form of neuropathy and chronic chemotherapy-induced peripheral neuropathy (CIPN). Anecdotal reports suggested that gabapentin may be helpful in the prevention of these toxicities. The purpose of this pilot study was to obtain data to support or refute the utility of pregabalin for the prevention of P-APS and CIPN.
Methods
Patients scheduled to receive weekly paclitaxel (80 mg/m
2
/dose) were randomized 1:1 to receive pregabalin 75 mg or a placebo, twice daily, during the 12 weeks of chemotherapy. Patients completed the European Organization of Research and Treatment of Cancer Quality of Life (EORTC QLQ) CIPN20 questionnaire at baseline, prior to each dose of paclitaxel and monthly for 6 months post-treatment. Patients completed a post-paclitaxel questionnaire for 6 days after each dose of paclitaxel and an acute pain syndrome symptom questionnaire on day 8. The primary end point was to determine the effect of pregabalin on the maximum of the worst acute pain scores for the week following paclitaxel administration for cycle 1.
Results
Forty-six patients were randomly assigned to the treatment or placebo arm. There was no suggestion of a difference between the two study arms with regard to P-APS measures. While there was a suggestion that pregabalin decreased numbness, there was no suggestion that it decreased tingling, pain, or the EORTC QLQ-CIPN20 subscale scores. There were no evident toxicity differences between the two study arms.
Conclusions
The results of this pilot trial do not support that pregabalin is helpful for preventing P-APS or paclitaxel-associated CIPN.
Publisher
Springer Berlin Heidelberg,Springer
Subject
Acute Pain - chemically induced
/ Acute Pain - prevention & control
/ Adult
/ Aged
/ Cyclohexanecarboxylic Acids - therapeutic use
/ Female
/ gamma-Aminobutyric Acid - therapeutic use
/ Humans
/ Hypesthesia - chemically induced
/ Hypesthesia - prevention & control
/ Male
/ Medicine
/ Nursing
/ Oncology
/ Paclitaxel - adverse effects
/ Paclitaxel - therapeutic use
/ Paresthesia - chemically induced
/ Paresthesia - prevention & control
/ Peripheral Nervous System Diseases - chemically induced
/ Peripheral Nervous System Diseases - prevention & control
/ Placebos
